QIAstat-Dx® Meningitis/Encephalitis Panel Performance Evaluation Study

CompletedOBSERVATIONAL
Enrollment

1,524

Participants

Timeline

Start Date

May 4, 2022

Primary Completion Date

March 2, 2023

Study Completion Date

March 2, 2023

Conditions
Meningitis/Encephalitis
Interventions
DEVICE

QIAstat-Dx® Meningitis/Encephalitis (ME) Panel

The performance of QIAstat-Dx® Meningitis/Encephalitis Panel will be evaluated in comparison with another validated comparator method, followed by bidirectional sequencing using residual specimens of cerebrospinal fluid (CSF) obtained by lumbar puncture from subjects with signs and symptoms of meningitis and/or encephalitis.

Trial Locations (1)

Unknown

Qiagen, Manchester

All Listed Sponsors
lead

QIAGEN Gaithersburg, Inc

INDUSTRY